HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Novel drugs against tuberculosis: a clinician's perspective.

Abstract
The United Nations Millennium Development Goal of reversing the global spread of tuberculosis by 2015 has been offset by the rampant re-emergence of drug-resistant tuberculosis, in particular fluoroquinolone-resistant multidrug-resistant and extensively drug-resistant tuberculosis. After decades of quiescence in the development of antituberculosis medications, bedaquiline and delamanid have been conditionally approved for the treatment of drug-resistant tuberculosis, while several other novel compounds (AZD5847, PA-824, SQ109 and sutezolid) have been evaluated in phase II clinical trials. Before novel drugs can find their place in the battle against drug-resistant tuberculosis, linezolid has been compassionately used with success in the treatment of fluoroquinolone-resistant multidrug-resistant tuberculosis. This review largely discusses six novel drugs that have been evaluated in phase II and III clinical trials, with focus on the clinical evidence for efficacy and safety, potential drug interactions, and prospect for using multiple novel drugs in new regimens.
AuthorsIoana Diana Olaru, Florian von Groote-Bidlingmaier, Jan Heyckendorf, Wing Wai Yew, Christoph Lange, Kwok Chiu Chang
JournalThe European respiratory journal (Eur Respir J) Vol. 45 Issue 4 Pg. 1119-31 (Apr 2015) ISSN: 1399-3003 [Electronic] England
PMID25431273 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
CopyrightCopyright ©ERS 2015.
Chemical References
  • Antitubercular Agents
  • Diarylquinolines
  • Ethylenediamines
  • N-geranyl-N'-(2-adamantyl)ethane-1,2-diamine
  • Nitroimidazoles
  • OPC-67683
  • Oxazoles
  • Oxazolidinones
  • PNU-100480
  • pretomanid
  • bedaquiline
  • Adamantane
Topics
  • Adamantane (analogs & derivatives, therapeutic use)
  • Antitubercular Agents (pharmacology, therapeutic use)
  • Clinical Trials, Phase II as Topic
  • Clinical Trials, Phase III as Topic
  • Diarylquinolines (therapeutic use)
  • Drug Therapy, Combination
  • Ethylenediamines (therapeutic use)
  • Extensively Drug-Resistant Tuberculosis (drug therapy)
  • Female
  • Follow-Up Studies
  • Humans
  • Male
  • Nitroimidazoles (therapeutic use)
  • Oxazoles (therapeutic use)
  • Oxazolidinones (therapeutic use)
  • Treatment Outcome
  • Tuberculosis, Multidrug-Resistant (drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: